Shift Technologies, Inc. logo

Shift Technologies, Inc. (SFT)

Market Closed
16 Jan, 20:00
NASDAQ (CM) NASDAQ (CM)
$
0. 17
0
0%
$
2.89M Market Cap
- P/E Ratio
- Div Yield
173.14M Volume
- Eps
$ 0.17
Previous Close
Add Transaction
Day Range
0.15 0.29
Year Range
0.15 0.29
Want to track SFT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Is Taboola Set to Gain From Advertising Shift to Digital Marketing?

Is Taboola Set to Gain From Advertising Shift to Digital Marketing?

TBLA expands beyond native ads with its Realize platform, AI tools, and key partnerships to capture digital ad growth.

Zacks | 1 year ago
Rivian's Q2 Deliveries Dip Amid Shift to 2026 Model-Year Vehicles

Rivian's Q2 Deliveries Dip Amid Shift to 2026 Model-Year Vehicles

RIVN's Q2 deliveries drop 22% as it prepares for 2026 models. However, a $1B Volkswagen investment fuels future growth.

Zacks | 1 year ago
4 Value Stocks to Invest in for the Second-Half 2025 Market Shift

4 Value Stocks to Invest in for the Second-Half 2025 Market Shift

Hudbay, StoneCo, Centene, and CVS stand out as top value picks for H2 2025 with strong cash flow and growth prospects.

Zacks | 1 year ago
Hyatt: A Buy On Favorable Valuations And Strategic Shift Toward Asset-Light Business

Hyatt: A Buy On Favorable Valuations And Strategic Shift Toward Asset-Light Business

Hyatt's shift to an asset-light, franchise model boosts capital efficiency and positions it for long-term growth with less capital risk. Despite management's cautious near-term outlook due to slowing US bookings, strong international growth and robust new room pipeline support high single-digit revenue growth. Hyatt's valuation is attractive relative to peers, with strong EBITDA growth justifying a higher EV/EBITDA multiple closer to Hilton than Marriott.

Seekingalpha | 1 year ago
Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Kura Oncology is a Strong Buy due to ziftomenib's positive Phase 2 data in newly diagnosed AML mutant patients and upcoming FDA Priority Review for relapsed/refractory NPM1-m/KMT2A-r AML. The pipeline is expanding beyond monotherapy, with promising results in combination regimens for newly diagnosed AML patients. Strong financials, including $703M in cash and a supportive partnership with Kyowa Kirin, minimize dilution risk and support operations through commercialization for 1st-line setting.

Seekingalpha | 1 year ago
Emerson Electric: Growth Boosted By Shift From Hardware To Software

Emerson Electric: Growth Boosted By Shift From Hardware To Software

Emerson Electric's strategic M&A has shifted its portfolio from hardware to higher-growth, higher-margin software, now comprising 31% of revenue. Our analysis shows Emerson's software segment enjoys both organic and inorganic growth, with competitive advantages in specialized industries like oil & gas, semiconductors, and life sciences. Strong integration between Emerson's hardware and software drives cross-selling, recurring revenue, and customer stickiness, leveraging its large installed base.

Seekingalpha | 1 year ago
6 Stocks Rocking a Shift Up to the Russell 1000 Index

6 Stocks Rocking a Shift Up to the Russell 1000 Index

Key Points in This Article: The 2025 FTSE Russell reconstitution completed its last annual event, creating opportunity in six stocks moving from Russell 2000 to the Russell 1000.

247wallst | 1 year ago
Shift4 Payments: Eyes 30% Annual Revenue Growth Through 2028 With Margin Expansion

Shift4 Payments: Eyes 30% Annual Revenue Growth Through 2028 With Margin Expansion

Shift4 Payments: Eyes 30% Annual Revenue Growth Through 2028 With Margin Expansion

Seekingalpha | 1 year ago
Shift4 Payments: Strong Buy On Inflection And Synergy Upside

Shift4 Payments: Strong Buy On Inflection And Synergy Upside

We Initiate Shift4 Payments with Strong Buy and $216 PT, citing robust volume growth, operating leverage, and early-stage cross-sell synergies. Shift4's margin expansion is accelerating, driven by disciplined integration of acquisitions and a scalable SaaS/payments platform, supporting sustained EBITDA outperformance. Valuation disconnect presents 135% upside; current multiples discount durable growth, margin leadership, and a deep enterprise backlog not fully reflected in peer comps.

Seekingalpha | 1 year ago
FOUR.PR.A: Shift4 Payments' 6.00% Mandatory Convertible Preferred Stock IPO

FOUR.PR.A: Shift4 Payments' 6.00% Mandatory Convertible Preferred Stock IPO

FOUR-A is a 6% mandatory convertible preferred stock from Shift4 Payments, offering exposure that is closely tied to common stock performance. FOUR-A's dividend coverage appears robust, with annual preferred payouts representing just 15% of expected 2025 earnings, supporting payment safety. Shift4 Payments has outperformed both the S&P 500 and the digital payments sector, with strong earnings growth and bullish analyst sentiment.

Seekingalpha | 1 year ago
RH Stock Rockets on Surprise Profit and Tariff Shift

RH Stock Rockets on Surprise Profit and Tariff Shift

Shares of RH NYSE: RH rocketed nearly 20% higher after the company delivered mixed first quarter earnings. Revenue of $814 million missed expectations for $818.1 billion.

Marketbeat | 1 year ago
Agree Realty Is Ready For The Next Market Shift

Agree Realty Is Ready For The Next Market Shift

Agree Realty is a defensive, growth-oriented REIT, thriving despite market volatility by focusing on essential, e-commerce-resistant tenants and disciplined portfolio management. ADC's record investments, low-cost long-term financing, and robust balance sheet (net debt/EBITDA 3.4x, no major maturities until 2028) set it apart from peers. The company's high-quality tenant mix, proactive asset management, and strong liquidity support sustainable dividend growth and reliable returns for investors.

Seekingalpha | 1 year ago
Loading...
Load More